Related Experiment Video

Updated: Aug 19, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Emerging prospects for the disease-modifying treatment of Alzheimer's disease

Lary C Walker1, Chris C Ibegbu, Charles W Todd

  • 1Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30322, USA. lary.walker@emory.edu <lary.walker@emory.edu>

Biochemical Pharmacology
|March 15, 2005
PubMed

Insights

Current Alzheimer's disease (AD) treatments offer only temporary relief. Research focuses on amyloid-beta (Abeta) protein accumulation, but new therapies require more relevant animal models for safety testing.

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • Approved Alzheimer's disease (AD) therapies primarily target neurotransmitter systems, offering palliative care without halting disease progression.
  • AD is characterized by the abnormal accumulation of amyloid-beta (Abeta) and tau proteins in the brain.
  • Evidence suggests Abeta aggregation plays a central role in the Alzheimer's proteopathic cascade.

Purpose of the Study:

  • To investigate the potential of Abeta-immunization therapy for Alzheimer's disease.
  • To address the safety concerns and side-effects observed with novel AD therapies.
  • To highlight the need for more biologically relevant animal models in AD research.

Main Methods:

  • Review of current Alzheimer's disease (AD) therapeutic strategies.
  • Analysis of preclinical data from rodent models.
  • Consideration of Abeta-immunization as a therapeutic approach.

Main Results:

  • Abeta-immunization therapy shows promise but has presented unexpected side-effects.
  • Preclinical studies in rodents did not predict these adverse events.
  • Existing therapies do not stop the neurodegenerative process in Alzheimer's disease.

Conclusions:

  • Novel Alzheimer's disease (AD) therapies, such as Abeta-immunization, require rigorous safety and efficacy evaluation.
  • Rodent models may not fully recapitulate the complexities of human AD pathology and treatment response.
  • Nonhuman primate models are proposed as a more suitable alternative for testing the safety and efficacy of emerging AD therapies.

More Related Videos

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...